Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
27-29 January, 2026
Not Confirmed
Not Confirmed
27-28 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
27-29 January, 2026
Industry Trade Show
Not Confirmed
27-28 January, 2026
Digital content
NEWS #PharmaBuzz
30 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251030498975/en/Staloral-Birch-Phase-III-Study-Successfully-Meets-Primary-Endpoint-Demonstrating-Efficacy-in-Children-and-Adolescents
03 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250903612776/en/Stallergenes-Greer-and-Nuance-Pharma-Enter-Exclusive-Long-term-Partnership-for-Actair-Sublingual-Immunotherapy-Tablet-for-the-Treatment-of-House-Dust-Mite-Allergy-in-China
30 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250730591660/en/Stallergenes-Greer-Announces-Palforzia-Featured-on-The-Balancing-Act-Airing-on-Lifetime-TV
03 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250702309702/en/Transition-of-Promotional-Activities-for-Allergen-Immunotherapy-Drug-Actair-in-Japan
12 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250611950731/en/Stallergenes-Greer-Showcases-Developments-in-Respiratory-and-Food-Allergy-Care-at-EAACI-2025
28 Feb 2025
// BUSINESSWIRE
Drugs in Development
Details:
The partnership aims for the development and commercialisation of Actair, Stallergenes Greer’s SLIT tablet for the treatment of house dust mite (HDM) induced allergic rhinitis.
Lead Product(s): House Dust Mite Allergen Extract
Therapeutic Area: Immunology Brand Name: Actair
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Nuance Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 03, 2025
Lead Product(s) : House Dust Mite Allergen Extract
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Nuance Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Stallergenes and Nuance Enter Exclusive Partnership for Actair Sublingual Immunotherapy
Details : The partnership aims for the development and commercialisation of Actair, Stallergenes Greer’s SLIT tablet for the treatment of house dust mite (HDM) induced allergic rhinitis.
Product Name : Actair
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 03, 2025
Details:
Palforzia is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Lead Product(s): Arachis Hypogaea Allergen
Therapeutic Area: Immunology Brand Name: Palforzia
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2025
Lead Product(s) : Arachis Hypogaea Allergen
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Palforzia® Peanut Allergy Therapy Now Available in U.S. for Ages 1 to 3 Years
Details : Palforzia is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Product Name : Palforzia
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 28, 2025
Details:
Palforzia is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Lead Product(s): Arachis Hypogaea Allergen
Therapeutic Area: Immunology Brand Name: Palforzia
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
Lead Product(s) : Arachis Hypogaea Allergen
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves Palforzia® for Toddlers with Peanut Allergy
Details : Palforzia is an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Product Name : Palforzia
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 09, 2025
Details:
Palforzia is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Lead Product(s): Arachis Hypogaea Allergen
Therapeutic Area: Immunology Brand Name: Palforzia
Study Phase: Phase IIIProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 02, 2024
Lead Product(s) : Arachis Hypogaea Allergen
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Palforzia® Gets Positive CHMP Opinion for Peanut Allergy in Toddlers
Details : Palforzia is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Product Name : Palforzia
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 02, 2024
Details:
Palforzia® is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Lead Product(s): Arachis Hypogaea Allergen
Therapeutic Area: Immunology Brand Name: Palforzia
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 30, 2024
Lead Product(s) : Arachis Hypogaea Allergen
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Pediatric Indication Extension for Palforzia® Oral Immunotherapy
Details : Palforzia® is in the U.S an oral immunotherapy treatment indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients.
Product Name : Palforzia
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 30, 2024
Details:
Through the divestment, Nestle sells its peanut-allergy treatment business to stallergenes greer, including Palforzia (peanut allergen powder-dnfp), an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis.
Lead Product(s): Arachis Hypogaea Allergen
Therapeutic Area: Immunology Brand Name: Palforzia
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Recipient: Nestle Health Sciences SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment September 04, 2023
Lead Product(s) : Arachis Hypogaea Allergen
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Nestle Health Sciences SA
Deal Size : Undisclosed
Deal Type : Divestment
Stallergenes Greer Announces Global Agreement with Nestlé Regarding the Peanut Allergy Oral Immun...
Details : Through the divestment, Nestle sells its peanut-allergy treatment business to stallergenes greer, including Palforzia (peanut allergen powder-dnfp), an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis.
Product Name : Palforzia
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
September 04, 2023
Details:
Staloral Staloral Birch is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma
Lead Product(s): Birch Pollen Extract
Therapeutic Area: Immunology Brand Name: Staloral Birch
Study Phase: Phase IIIProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 25, 2023
Lead Product(s) : Birch Pollen Extract
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch
Details : Staloral Staloral Birch is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma
Product Name : Staloral Birch
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 25, 2023
Details:
Staloral Birch 300 IR is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinoconjunctivitis, Allergic.
Lead Product(s): Staloral Birch 300 IR
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 29, 2022
Lead Product(s) : Staloral Birch 300 IR
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-indu...
Details : Staloral Birch 300 IR is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinoconjunctivitis, Allergic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 29, 2022
Details:
Study results were consistent across all age groups showed a reduction of risk of asthma onset of more than 20% observed in patients undergoing treatment with sublingual liquid AIT and symptomatic drugs versus patients treated with symptomatic drugs only.
Lead Product(s): Allergen Extract
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Staloral
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 02, 2022
Lead Product(s) : Allergen Extract
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study results were consistent across all age groups showed a reduction of risk of asthma onset of more than 20% observed in patients undergoing treatment with sublingual liquid AIT and symptomatic drugs versus patients treated with symptomatic drugs only...
Product Name : Staloral
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 02, 2022
Details:
The STAGR320 phase III clinical trial, which included 1,600 patients from 231 participating investigative sites in 13 countries, assessed the treatment of HDM-induced allergic rhinitis in adult and adolescent patients.
Lead Product(s): House Dust Mite Allergen Extract
Therapeutic Area: Immunology Brand Name: Actair
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2021
Lead Product(s) : House Dust Mite Allergen Extract
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The STAGR320 phase III clinical trial, which included 1,600 patients from 231 participating investigative sites in 13 countries, assessed the treatment of HDM-induced allergic rhinitis in adult and adolescent patients.
Product Name : Actair
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
Inspections and registrations
ABOUT THIS PAGE
Share 
